Martin van den Bent

78PUBLICATIONS
465CO-AUTHORS
Molecular targetsPredictive and prognostic markersRadiation therapyCancer diagnosisLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (78)

|Sep 17, 2026
Multidisciplinary recommendations for routine follow-up of isocitrate dehydrogenase‑mutant glioma in 2026: Adapting clinical practice to the molecular era.

|Aug 19, 2026
Exploring the landscape of targetable alterations in patients with glioblastoma.

|Jul 02, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

|May 25, 2026
Surgical resection or bevacizumab for treatment of radiation necrosis-associated cerebral edema in patients with brain metastases: A single center experience.

|Mar 27, 2026
Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target.

Rosa Luning, Sybren L N Maas, Pim J French

|Aug 31, 2025
cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors.

Pieter Wesseling, David Capper, Guido Reifenberger

Pageof 13

Frequent Collaborators

24 joint publications

Michael Weller

19 joint publications

Pim J French

15 joint publications

Matthias Preusser

15 joint publications

Wolfgang Wick